Disease-A-Month
Volume 55, Issue 11 , Pages 704-718 , November 2009

Treatment of Sarcoidosis

References 

  1. Israel HL, Sones M, Harrell D. Cortisone treatment of sarcoidosis: Experience with thirty-six cases. J Am Med Assoc. 1954;156:461–466
  2. Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533–548
  3. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;CD001114
  4. Statement on sarcoidosis (Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS Board Of Directors and by the ERS Executive Committee, February 1999). Am J Respir Crit Care Med. 1999;160:736–755
  5. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis. 1988;5:106–110
  6. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: A double-blind, placebo-controlled study (Dutch Study Group on Pulmonary Sarcoidosis). Eur Respir J. 1995;8:682–688
  7. Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002;121:24–31
  8. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–51
  9. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update. Arthritis Rheum. 2001;44:1496–1503
  10. Vucinic VM. What is the future of methotrexate in sarcoidosis? (A study and review). Curr Opin Pulm Med. 2002;8:470–476
  11. Rose AS, Tielker MA, Knox KS. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med. 2008;29:509–524
  12. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–66
  13. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–851
  14. Baughman RP, Koehler A, Bejarano PA, et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 2003;163:615–620
  15. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999;54:742–746
  16. Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68:1361–1383
  17. Hassid S, Choufani G, Saussez S, et al. Sarcoidosis of the paranasal sinuses treated with hydroxychloroquine. Postgrad Med J. 1998;74:172–174
  18. James DG, Barter S, Jash D, et al. Sarcoidosis of the upper respiratory tract (SURT). J Laryngol Otol. 1982;96:711–718
  19. Barre PE, Gascon-Barre M, Meakins JL, et al. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med. 1987;82:1259–1262
  20. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55:1248–1254
  21. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–197
  22. Denys BG, Bogaerts Y, Coenegrachts KL, et al. Steroid-resistant sarcoidosis: Is antagonism of TNF-alpha the answer?. Clin Sci Lond. 2007;112:281–289
  23. Santos E, Shaunak S, Renowden SA, et al. Treatment of refractory neurosarcoidosis with infliximab. J Neurol Neurosurg Psychiatry. 2008;(Epub ahead of print)
  24. Barnabe C, McMeekin J, Howarth A, et al. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol. 2008;35:1686–1687
  25. Stagaki E, Mountford WK, Lackland DT, et al. The treatment of lupus pernio: The results of 116 treatment courses in 54 patients. Chest. 2009;135:468–476
  26. Rosen T, Doherty C. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Dermatol Online J. 2007;13:14
  27. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201–208
  28. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J. 2008;31:1189–1196
  29. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–686
  30. Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med. 2007;28:134–140
  31. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis (The relationship of relapse to corticosteroid therapy). Chest. 1997;111:623–631
  32. Mihailovic-Vucinic V, Jovanovic D. Pulmonary sarcoidosis. Clin Chest Med. 2008;29:459–473
  33. O'Donnell AE. Bronchiectasis. Chest. 2008;134:815–823
  34. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med. 2008;29:549–563
  35. Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med. 2008;29:493–508
  36. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–282
  37. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  38. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010
  39. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis—Diagnosis and management. QJM. 1999;92:103–117
  40. Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med. 2008;29:475–492
  41. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000;84:110–116
  42. Sharma OP. Hypercalcemia in granulomatous disorders: A clinical review. Curr Opin Pulm Med. 2000;6:442–447
  43. Berliner AR, Haas M, Choi MJ. Sarcoidosis: The nephrologist's perspective. Am J Kidney Dis. 2006;48:856–870
  44. Requena L, Yus ES. Erythema nodosum. Dermatol Clin. 2008;26:425–438
  45. Wirnsberger RM, de Vries J, Breteler MH, et al. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92:750–756
  46. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133:1189–1195

 No financial or other potential conflicts of interest exist for the above authors. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

PII: S0011-5029(09)00080-7

doi: 10.1016/j.disamonth.2009.06.002

Disease-A-Month
Volume 55, Issue 11 , Pages 704-718 , November 2009

Article Tools